Acorda Therapeutics to Present at the Piper Jaffray Second Annual London Health Care Conference.HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will present at the upcoming Piper Jaffray Second Annual London Health Care Conference on Thursday, June 21, 2007 at 11:40 am British Summer Time British Summer Time Noun a time set one hour ahead of Greenwich Mean Time: used in Britain from the end of March to the end of October, providing an extra hour of daylight in the evening Abbrev: (BST) (BST (convention) BST - British Summer Time. The name for daylight-saving time in the UK GMT time zone. ), 6:40 am Eastern Daylight Time (EDT). The conference is taking place at The Great Eastern Hotel, Corner of Liverpool Street & Bishopsgate, London EC2M 7QN. The presentation will be available via a live webcast at http://www.corporate-ir.net/ireye/conflobby.zhtml? ticker=ACOR&item_id=1573789. (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) Archived versions of the webcast will be available for 90 days on our website at http://phx.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-irhome. Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda is conducting a Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion